Content validity of the National Comprehensive Cancer Network – Functional Assessment of Cancer Therapy – Breast Cancer Symptom Index (NFBSI-16) and Patient-Reported Outcomes Measurement Information System (PROMIS) Physical Function Short Form with advanced breast cancer patients-Reference-Cited by-同舟云学术

Content validity of the National Comprehensive Cancer Network – Functional Assessment of Cancer Therapy – Breast Cancer Symptom Index (NFBSI-16) and Patient-Reported Outcomes Measurement Information System (PROMIS) Physical Function Short Form with advanced breast cancer patients

Published:2019-05-29 Issue:1 Volume:17 Page:
ISSN:1477-7525
Container-title:Health and Quality of Life Outcomes
language:en
Short-container-title:Health Qual Life Outcomes

Author:

Krohe Meaghan^ORCID,Tang Derek H.,Klooster Brittany,Revicki Dennis,Galipeau Nina,Cella David

Funder

Novartis Pharmaceuticals Corporation

Publisher

Springer Science and Business Media LLC

Subject

Public Health, Environmental and Occupational Health,General Medicine

Link

http://link.springer.com/content/pdf/10.1186/s12955-019-1162-5.pdf

Reference27 articles.

1. National Cancer Institute. Stages of breast Cancer. 2014. http://www.cancer.gov/cancertopics/pdq/treatment/breast/Patient/page2 . Accessed 2/11/2016.

2. Baselga J, Campone M, Piccart M, Burris HA 3rd, Rugo HS, Sahmoud T, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med. 2012;366(6):520–9. https://doi.org/10.1056/NEJMoa1109653 .

3. Cardoso F, Costa A, Norton L, Cameron D, Cufer T, Fallowfield L, et al. 1st international consensus guidelines for advanced breast cancer (ABC 1). Breast. 2012;21(3):242–52. https://doi.org/10.1016/j.breast.2012.03.003 .

4. Burris HA 3rd, Lebrun F, Rugo HS, Beck JT, Piccart M, Neven P, et al. Health-related quality of life of patients with advanced breast cancer treated with everolimus plus exemestane versus placebo plus exemestane in the phase 3, randomized, controlled, BOLERO-2 trial. Cancer. 2013;119(10):1908–15. https://doi.org/10.1002/cncr.28010 .

5. Harbeck N, Iyer S, Turner N, Cristofanilli M, Ro J, Andre F, et al. Quality of life with palbociclib plus fulvestrant in previously treated hormone receptor-positive, HER2-negative metastatic breast cancer: patient-reported outcomes from the PALOMA-3 trial. Ann Oncol. 2016;27(6):1047–54. https://doi.org/10.1093/annonc/mdw139 .

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Validity, reliability, responsiveness, and clinically meaningful change threshold estimates of the National Comprehensive Cancer Network-Functional Assessment of Cancer Therapy-Breast Cancer Symptom Index (NFBSI-16);Journal of Patient-Reported Outcomes;2024-08-15

2. Comparison of the effects of high-intensity interval and moderate-intensity continuous training on inflammatory markers, cardiorespiratory fitness, and quality of life in breast cancer patients;Journal of Sport and Health Science;2023-11

3. An exploration of proactive health oriented symptom patterns in patients undergoing percutaneous coronary intervention with stent implantation: A mixed-methods study protocol;PLOS ONE;2023-10-05

4. A systematic review of physical function tests as predictors of key clinical outcomes for adults with blood cancers;Supportive Care in Cancer;2023-09

5. Characterization of Physical Function and Cancer-Related Physical Impairments in Hispanic Women With Breast Cancer: A Descriptive Study;Hispanic Health Care International;2023-06-20